Bradykinin receptors in mouse and rat isolated superior cervical ganglia.
1. The ability of bradykinin and its analogues to depolarize rat and mouse superior cervical ganglia was studied by use of in vitro grease-gap recording techniques, and the ability of antagonists selective for bradykinin receptor subtypes to block their effects was examined. 2. Bradykinin (3 microM) depolarized ganglia from both species, although the magnitude of the maximal response was less in mouse (15 +/- 5%, n = 7) than rat tissue (33 +/- 6%, n = 7), relative to muscarine (1 microM). 3. Interleukin 1 beta (30 u ml-1 for 18 h at 37 degrees C) increased the depolarization caused by bradykinin (3 microM) in mouse ganglia from 15% to 54% (P < 0.001, n = 12). Responses to the B1 receptor agonist, [des-Arg10]-kallidin (3 microM) were similarly potentiated but this was only detected after inhibition of peptidase activity with 10 microM captopril (4% to 35%, n = 5). 4. In ganglia from both species the rank order of agonist potency was bradykinin = [Lys0]-bradykinin >> [des-Arg10]-kallidin. However, like responses to [des-Arg10]-kallidin in mouse tissue, both the potency of bradykinin and the maximal depolarization achieved (EC50 = 912 nM; 80%, n = 11) was enhanced following inhibition of angiotensin converting enzyme with 10 microM captopril (EC50 = 50 nM; 135%, n = 4). 5. Responses to bradykinin were selectively antagonized by the B2 receptor antagonist, Hoe 140 but not by the B1 antagonist, [Leu8]-bradykinin1-8. From Schild analysis the pA2 value for Hoe 140 in mouse tissue was 9.65, although the slope of the regression line was significantly greater than unity, indicating non-competitive kinetics (slope = 1.88 +/- 0.18, n = 9). The depolarization caused by [Lys0]-bradykinin was also antagonized by Hoe 140 (3 nM).6. Thus the predominant bradykinin receptor in mouse superior cervical ganglia is compatible with a B2 subtype. Furthermore the depolarizations caused by B1 and B2 agonists in this tissue can be increased following exposure to interleukin l beta, and by blocking peptide degradation with captopril.
Seabrook
G R
GR
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex.
Bowery
B J
BJ
Hill
R G
RG
D000595:Amino Acid Sequence; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D004594:Electrophysiology; D007375:Interleukin-1 / Q000494:pharmacology; D007609:Kallidin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009116:Muscarine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018002:Receptors, Bradykinin / Q000819:agonists / Q000378:metabolism*; D013329:Structure-Activity Relationship; D017783:Superior Cervical Ganglion / Q000187:drug effects / Q000378:metabolism*
D065168:Bradykinin Receptor Antagonists; D007375:Interleukin-1; D018002:Receptors, Bradykinin; C095632:bradykinin, Leu(8)-; D007609:Kallidin; C052787:kallidin, des-Arg(10)-; C065679:icatibant; D009116:Muscarine; D001920:Bradykinin